Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: NRM004
MIFTS: 52

Neuroma

Categories: Cancer diseases, Neuronal diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Neuroma

About this section

MalaCards integrated aliases for Neuroma:

Name: Neuroma 12 56 45 15 17 74

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Neuronal diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:2001
MeSH 45 D009463
NCIt 51 C3275
SNOMED-CT 69 25169009
UMLS 74 C0027858
Sources

Summaries for Neuroma

About this section
Disease Ontology : 12 A nervous system benign neoplasm that is characterized as a nerve tissue tumor.

MalaCards based summary : Neuroma is related to acoustic neuroma and multiple mucosal neuroma. An important gene associated with Neuroma is ANK3 (Ankyrin 3), and among its related pathways/superpathways are Signaling by GPCR and Developmental Biology. The drugs Bupivacaine and Mepivacaine have been mentioned in the context of this disorder. Affiliated tissues include brain, bone and thyroid, and related phenotypes are behavior/neurological and cardiovascular system

Wikipedia : 77 A neuroma (/njʊəˈroʊmə/; plural: neuromata or neuromas) is a growth or tumor of nerve tissue. Neuromas... more...

Sources

Related Diseases for Neuroma

About this section

Diseases related to Neuroma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 296)
# Related Disease Score Top Affiliating Genes
1 acoustic neuroma 34.0 BICRA NF1 NF2 TGFB1
2 multiple mucosal neuroma 33.8 ENO2 RET
3 neurofibromatosis, type iv, of riccardi 33.0 NF1 NF2 RET
4 multiple endocrine neoplasia, type iib 32.7 CALCA GDNF RET
5 neurofibroma 30.5 NF1 NF2 S100B
6 hydrocephalus 30.3 ENO2 GFAP NGF TGFB1
7 spinal meningioma 30.3 ENO2 NF1 NF2
8 neurilemmoma 30.2 ENO2 GFAP NF1 NF2 S100B
9 bednar tumor 30.2 ENO2 S100B
10 benign ependymoma 30.1 ENO2 GFAP NF2
11 plexiform neurofibroma 30.1 ANK3 NF1 NF2
12 meningioma, familial 30.1 ENO2 GFAP NF1 NF2
13 hemangioma 30.0 ENO2 FGF2 RET
14 thyroid carcinoma, familial medullary 29.9 CALCA ENO2 GDNF RET
15 ependymoma 29.9 ENO2 GFAP NF2 S100B
16 malignant peripheral nerve sheath tumor 29.8 NF1 NF2 S100B
17 neurofibrosarcoma 29.7 NF1 NF2
18 multiple endocrine neoplasia 29.7 CALCA GDNF NF1 RET
19 pheochromocytoma 29.1 CALCA ENO2 GDNF NF1 NGF RET
20 neuroma biliary tract 12.1
21 neurofibromatosis, type ii 11.5
22 neurofibromatosis, type i 11.5
23 klumpke paralysis 11.1
24 erb-duchenne and dejerine-klumpke palsies 11.1
25 cerebral convexity meningioma 10.4 GFAP NF2
26 meningothelial meningioma 10.4 ENO2 NF2
27 intraventricular meningioma 10.4 GFAP NF2
28 primitive neuroectodermal tumor of the cervix uteri 10.4 ENO2 GFAP
29 melanotic medulloblastoma 10.4 ENO2 GFAP
30 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 10.4
31 rhabdoid meningioma 10.4 GFAP NF2
32 gemistocytic astrocytoma 10.4 GFAP S100B
33 cerebellar medulloblastoma 10.4 ENO2 GFAP
34 fibrous meningioma 10.4 NF2 S100B
35 syringocystadenoma papilliferum 10.4 GFAP S100B
36 ossifying fibromyxoid tumor 10.4 ENO2 S100B
37 central nervous system primitive neuroectodermal neoplasm 10.4 ENO2 GFAP
38 clear cell ependymoma 10.4 ENO2 GFAP
39 chordoid meningioma 10.4 GFAP S100B
40 spinal cancer 10.4 GFAP NF2
41 askin's tumor 10.4 ENO2 NGF
42 dysembryoplastic neuroepithelial tumor 10.4 GFAP S100B
43 lesion of sciatic nerve 10.4 NGF SCN10A
44 spindle cell rhabdomyosarcoma 10.4 GFAP S100B
45 middle cerebral artery infarction 10.4 ENO2 S100B
46 subependymal glioma 10.3 ENO2 GFAP
47 chordoid glioma 10.3 GFAP NF2 S100B
48 intracranial cysts 10.3 ENO2 GFAP S100B
49 anaplastic ependymoma 10.3 GFAP NF2 S100B
50 facial paralysis 10.3

Graphical network of the top 20 diseases related to Neuroma:



Diseases related to Neuroma
Sources

Symptoms & Phenotypes for Neuroma

About this section

MGI Mouse Phenotypes related to Neuroma:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.27 ANK3 ENO2 FGF2 GDNF GFAP NF1
2 cardiovascular system MP:0005385 10.13 ACTA2 FGF2 GDNF GFAP NF1 NGF
3 mortality/aging MP:0010768 10.11 ANK3 FGF2 GDNF GFAP NF1 NF2
4 growth/size/body region MP:0005378 10.1 ENO2 GDNF GFAP NF1 NF2 NGF
5 muscle MP:0005369 9.97 ACTA2 FGF2 GDNF GFAP NF1 NGF
6 nervous system MP:0003631 9.97 ANK3 ENO2 FGF2 GDNF GFAP NF1
7 neoplasm MP:0002006 9.73 FGF2 NF1 NF2 NRP1 RET TGFB1
8 respiratory system MP:0005388 9.5 ANK3 ENO2 NF1 NF2 RET SCN10A
9 vision/eye MP:0005391 9.28 ACTA2 FGF2 GFAP NF1 NF2 NGF
Sources

Drugs & Therapeutics for Neuroma

About this section

Drugs for Neuroma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 116)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bupivacaine Approved, Investigational Phase 4,Not Applicable 38396-39-3, 2180-92-9 2474
2
Mepivacaine Approved, Vet_approved Phase 4 96-88-8 4062
3
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
4 Anti-Infective Agents Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
5 Gentamicins Phase 4,Not Applicable
6 Anti-Bacterial Agents Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
7 Anesthetics Phase 4,Phase 1,Not Applicable,Early Phase 1
8 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
9 Anesthetics, Local Phase 4,Phase 1,Not Applicable,Early Phase 1
10 Central Nervous System Depressants Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
11 Anti-Inflammatory Agents Phase 4,Phase 2,Not Applicable
12 glucocorticoids Phase 4,Not Applicable
13 Hormones Phase 4,Not Applicable
14 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Not Applicable
15 Hormone Antagonists Phase 4,Not Applicable
16 Immunologic Factors Phase 4,Phase 2,Phase 1,Early Phase 1
17 Immunosuppressive Agents Phase 4,Phase 2,Phase 1,Early Phase 1
18 Triamcinolone hexacetonide Phase 4
19 triamcinolone acetonide Phase 4
20 Triamcinolone diacetate Phase 4
21
Capsaicin Approved Phase 2,Phase 1 404-86-4 1548943
22
Bevacizumab Approved, Investigational Phase 2,Phase 1 216974-75-3
23
Morphine Approved, Investigational Phase 2 57-27-2 5288826
24
Mexiletine Approved, Investigational Phase 2 31828-71-4 4178
25
Sirolimus Approved, Investigational Phase 2,Phase 1,Early Phase 1 53123-88-9 46835353 5284616 6436030
26
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
27
Everolimus Approved Phase 2,Phase 1,Early Phase 1 159351-69-6 70789204 6442177
28
Acetylcholine Approved, Investigational Phase 2,Not Applicable 51-84-3 187
29
Aspirin Approved, Vet_approved Phase 2 50-78-2 2244
30
Axitinib Approved, Investigational Phase 2 319460-85-0 6450551
31
Histamine Approved, Investigational Phase 2 51-45-6 774
32
Betahistine Approved, Investigational Phase 2 5638-76-6 2366
33
Lapatinib Approved March 2007, Investigational Phase 2,Early Phase 1 231277-92-2, 388082-78-8 208908 9941095
34
Lactitol Investigational Phase 2 585-88-6, 585-86-4 493591
35 Antibodies, Monoclonal Phase 2,Phase 1
36 Antineoplastic Agents, Immunological Phase 2,Phase 1
37 Antibodies Phase 2,Phase 1
38 Angiogenesis Inhibitors Phase 2,Phase 1
39 Immunoglobulins Phase 2,Phase 1
40 Angiogenesis Modulating Agents Phase 2,Phase 1
41 Protein Kinase Inhibitors Phase 2,Early Phase 1
42 Anti-Arrhythmia Agents Phase 2,Phase 1,Early Phase 1,Not Applicable
43 Analgesics Phase 2,Not Applicable
44 Sodium Channel Blockers Phase 2,Phase 1,Early Phase 1,Not Applicable
45 Diuretics, Potassium Sparing Phase 2,Phase 1,Early Phase 1,Not Applicable
46 Narcotics Phase 2
47 Analgesics, Opioid Phase 2
48 Endostatins Phase 2 71581480
49 Antibiotics, Antitubercular Phase 2,Phase 1,Early Phase 1
50 Antifungal Agents Phase 2,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 126)
# Name Status NCT ID Phase Drugs
1 Gentamicin Treatment Prior to Schwannoma Surgery - Residual Function Unknown status NCT02379754 Phase 4 Gentamicins
2 Pathophysiology of Post Amputation Pain Completed NCT01632709 Phase 4 Bupivacaine;Placebo
3 A Comparative Post-marketing Study of Commercially Available Peripheral Nerve Gap Repair Options Completed NCT00948025 Phase 4
4 Blind and Ultrasound Guided Injection in Morton Neuroma Recruiting NCT03046108 Phase 4 blind injection of Mepivacaine;blind injection of Triamcinolone;guided injection of mepivacaine;guided injection of Triamcinolone
5 Gentamicin Treatment Prior to Schwannoma Surgery - No Residual Function Recruiting NCT02415257 Phase 4 Gentamicin
6 Intranasal Neurostimulation in Ameliorating Symptoms of Neuropathic Corneal Pain Recruiting NCT03674892 Phase 4
7 Stereotactic Radiation in Vestibular Schwannoma Unknown status NCT01449604 Phase 3
8 Cyberknife Radiosurgery for Patients With Neurinomas Recruiting NCT02055859 Phase 3
9 Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Unknown status NCT02934256 Phase 2 Icotinib
10 A Study to Evaluate the Efficacy and Safety of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma) Completed NCT02283957 Phase 2 CNTX-4975
11 ALGRX 4975 in the Treatment of Patients With Morton's Neuroma Completed NCT00130962 Phase 2 ALGRX 4975
12 A Study to Evaluate the Safety and Efficacy of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma) Completed NCT02678793 Phase 2 CNTX-4975
13 Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2) Completed NCT01207687 Phase 2
14 Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Completed NCT00973739 Phase 2 Lapatinib
15 Phase II Study of the Multichannel Auditory Brain Stem Implant for Deafness Following Surgery for Neurofibromatosis 2 Completed NCT00004437 Phase 2
16 Efficacy of Opioids and Mexiletine for the Treatment of Postamputation Pain Completed NCT00383682 Phase 2 morphine and mexiletine
17 Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Completed NCT02104323 Phase 2 Endostatin
18 Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients Completed NCT01490476 Phase 2 RAD001
19 Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2 Completed NCT01419639 Phase 2 Everolimus (RAD001) , Afinitor®
20 RGD PET/MRI in Sporadic Vestibular Schwannoma Recruiting NCT03393689 Phase 2 One injection of 68Ga-NODAGA-E[c(RGDyK)]2
21 Hearing Outcomes Using Fractionated Proton Radiation Therapy for Vestibular Schwannoma Recruiting NCT01199978 Phase 2
22 Study of Aspirin in Patients With Vestibular Schwannoma Recruiting NCT03079999 Phase 2 Aspirin;Placebo
23 Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas Recruiting NCT03231306 Phase 2 Binimetinib
24 Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors Recruiting NCT03095248 Phase 2 Selumetinib
25 Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma Active, not recruiting NCT01345136 Phase 2 RAD001, everolimus
26 Axillary Reverse Mapping Active, not recruiting NCT00572481 Phase 2
27 AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas Active, not recruiting NCT02831257 Phase 2 AZD2014
28 Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas Active, not recruiting NCT02129647 Phase 2 Axitinib
29 Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas Active, not recruiting NCT01767792 Phase 2 Bevacizumab
30 Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas Active, not recruiting NCT01125046 Phase 2
31 AM-125 in the Treatment of Acute Peripheral Vertigo Following Vestibular Schwannoma Resection Not yet recruiting NCT03908567 Phase 2 Intranasal Drug;Oral Tablet
32 A Study of Nilotinib in Growing Vestibular Schwannomas Terminated NCT01201538 Phase 2 Nilotinib
33 PTC299 for Treatment of Neurofibromatosis Type 2 Terminated NCT00911248 Phase 2 PTC299
34 Antineoplaston Therapy in Treating Patients With Neurofibroma and Schwannoma Terminated NCT02988726 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
35 Botulinum Toxin Type A for Neuroma Pain Withdrawn NCT01374191 Phase 2 onabotulinum toxin type-A;2nd phase - onabotulinum toxin type-A
36 Study of CPI-0610 in Patients With Malignant Peripheral Nerve Sheath Tumors Withdrawn NCT02986919 Phase 2 CPI-0610
37 Compare Ultrasound Assisted Cold Therapy and Lidocaine Injection to Treat Morton's Neuroma Completed NCT02838758 Phase 1 Lidocaine;Saline
38 Study to Evaluate the Safety and Tolerability of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma) Completed NCT02550756 Phase 1 CTNX-4975
39 RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma Completed NCT01119599 Phase 1 Gamma-Secretase Inhibitor RO4929097;Temozolomide
40 EYE001 to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome Completed NCT00056199 Phase 1 EYE001
41 An Implant for Hearing Loss Due to Removal of Neurofibromatosis 2 Tumors Completed NCT00030043 Phase 1
42 Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease Recruiting NCT01552434 Phase 1 Temsirolimus;Valproic Acid
43 Targeted Imaging of Glutamate Carboxypeptidase II With DCFPyL-PET Recruiting NCT03542773 Phase 1 18F-DCFPyL Injection
44 Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Vestibular Schwannoma Suspended NCT01083966 Phase 1 Bevacizumab (Avastin)
45 Morton's Neuroma: Manipulation Versus Steroid Injection Unknown status NCT02304094 Not Applicable methylprednisolone
46 Comparison of Alcohol and Steroid Injection for Treating Morton's Neuroma Unknown status NCT00284583 Not Applicable Injection of Steroid into Foot;Injection of Alcohol into Foot;Injection of Lidocaine into Foot
47 Neuroma Injections to Treat Restless Legs Syndrome - RCT Unknown status NCT00656110 Not Applicable equal parts of 0.5% plain Marcaine and 2% lidocaine mixed with 0.8 mg Depo-medrol/4% absolute alcohol in a total injection volume of 1 ml;Normal saline - 1ml
48 Effect of Implant Position on Magnetic Resonance Image Distortion Unknown status NCT02246231 Not Applicable
49 Response Prediction After GKS in Patients With Vestibular Schwannoma Using DCE MR Imaging Unknown status NCT03097822
50 Preoperative Vestibular Rehabilitation Effectiveness After Vestibular Schwannoma Surgery Unknown status NCT02275325 Not Applicable

Search NIH Clinical Center for Neuroma

Cochrane evidence based reviews: neuroma

Sources

Genetic Tests for Neuroma

About this section
Sources

Anatomical Context for Neuroma

About this section

MalaCards organs/tissues related to Neuroma:

42
Brain, Bone, Thyroid, Skin, Testes, Spinal Cord, Pituitary
Sources

Publications for Neuroma

About this section

Articles related to Neuroma:

(show top 50) (show all 2266)
# Title Authors Year
1
Increased Hospital Surgical Volume Reduces Rate of 30- and 90-Day Readmission After Acoustic Neuroma Surgery. ( 29889284 )
2019
2
Acoustic neuroma quality of life: are we missing the point? ( 29948270 )
2019
3
Topical insulin in neurotrophic keratopathy after resection of acoustic neuroma. ( 30025986 )
2019
4
Primary Glioblastoma of Cerebellopontine Angle in Adult Mimicking Acoustic Neuroma. ( 30347301 )
2019
5
Long-Term Tumor Control Rates Following Gamma Knife Radiosurgery for Acoustic Neuroma. ( 30447465 )
2019
6
Hearing preservation in small acoustic neuroma: observation or active therapy? Literature review and institutional experience. ( 30535851 )
2019
7
Spontaneous Shrinkage of Cystic Acoustic Neuroma: A Case Report. ( 30685372 )
2019
8
Influence of Selection Bias in Survey Studies Derived From a Patient-Focused Organization: A Comparison of Response Data From a Single Tertiary Care Center and the Acoustic Neuroma Association. ( 30807524 )
2019
9
Influence of Selection Bias in Survey Studies Derived From a Patient-Focused Organization: A Comparison of Response Data From a Single Tertiary Care Center and the Acoustic Neuroma Association. ( 30870367 )
2019
10
Hand-Held Thulium Laser Fiber And Ultrasonic Aspirator For Opening The Internal Auditory Canal During Acoustic Neuroma Microneurosurgery: Operative Technique. ( 30928583 )
2019
11
Noise exposure as a risk factor for acoustic neuroma: a systematic review and meta-analysis. ( 31012775 )
2019
12
Validation of self-reported occupational noise exposure in participants of a French case-control study on acoustic neuroma. ( 31028471 )
2019
13
Is endoscopic inspection necessary to detect residual disease in acoustic neuroma surgery? ( 31028535 )
2019
14
An investigation of life quality of patients after two different acoustic neuroma resections. ( 31050576 )
2019
15
Vestibular Traumatic Neuroma Following Temporal Bone Fracture. ( 30531646 )
2019
16
Intraluminal capillary hemangioma of the foot presenting clinically as a neuroma: A case report. ( 30978660 )
2019
17
Hypercellular Encapsulated Neuroma Imitating Desmoplastic Melanoma. ( 30531539 )
2019
18
Traumatic Neuroma With Melanoma Perineural Invasion. ( 30045073 )
2019
19
Short term comparison between blind and ultrasound guided injection in morton neuroma. ( 30062527 )
2019
20
Prediction of Clinical Prognosis according to Intermetatarsal Distance and Neuroma Size on Ultrasonography in Morton Neuroma: A Prospective Observational Study. ( 30244477 )
2019
21
Amputation neuroma of the vagal nerve simulating celiac lymph node enlargement: diagnosis with EUS-FNA. ( 30472205 )
2019
22
Etiology and Treatment Outcomes for Sural Neuroma. ( 30712380 )
2019
23
An aligned nanofiber nerve conduit that inhibits painful traumatic neuroma formation through regulation of the RhoA/ROCK signaling pathway. ( 30717043 )
2019
24
Targeted Muscle Reinnervation for Prosthesis Optimization and Neuroma Management in the Setting of Transradial Amputation. ( 30733097 )
2019
25
Morton's interdigital neuroma: instructional review. ( 30800476 )
2019
26
The effectiveness of non-surgical interventions for common plantar digital compressive neuropathy (Morton's neuroma): a systematic review and meta-analysis. ( 30809275 )
2019
27
Palisaded Encapsulated (Solitary Circumscribed) Neuroma: A Review of 30 Cases. ( 30834800 )
2019
28
Nerve capping technique with nerve conduit for treating painful digital neuroma: A case report. ( 30853276 )
2019
29
Diagnostic Criteria for Symptomatic Neuroma. ( 30855369 )
2019
30
Surgery for Symptomatic Neuroma: Anatomic Distribution and Predictors of Secondary Surgery. ( 30907815 )
2019
31
Effect of Nerve-Cutting Technique on Nerve Microstructure and Neuroma Formation. ( 30911209 )
2019
32
Expansile Traumatic Neuroma of the Intratemporal Facial Nerve. ( 30941279 )
2019
33
Nerve capping with a nerve conduit for the treatment of painful neuroma in the rat sciatic nerve ( 30964248 )
2019
34
Traumatic neuroma of the posterior tibial nerve due to previous surgery presenting as a massive tumor in the midfoot: A case report. ( 30974343 )
2019
35
Painful Vater-Pacini neuroma of the digit in neurofibromatosis type 1. ( 30984511 )
2019
36
Traumatic neuroma in mastectomy scar: Two case reports and review of the literature. ( 30985684 )
2019
37
Regular swimming exercise attenuated neuroma pain in rats: involvement of leptin and adiponectin. ( 30986512 )
2019
38
Post-traumatic neuroma of the breast in a 52-year-old female with a remote history of breast augmentation and explantation. ( 30990244 )
2019
39
Mechanical Diagnosis and Therapy and Morton's Neuroma: A Case Report. ( 31040508 )
2019
40
Can percutaneous alcoholization of Morton's neuroma with phenol by electrostimulation guidance be an alternative to surgical excision? Long-term results. ( 31064701 )
2019
41
Evaluation of Auditory Pathways Using DTI in Patients Treated with Gamma Knife Radiosurgery for Acoustic Neuroma: A Preliminary Report. ( 28258282 )
2018
42
Increased sensibility to acute acoustic and blast trauma among patients with acoustic neuroma. ( 29184217 )
2018
43
Transcanal Transpromontorial Acoustic Neuroma Surgery: Results and Facial Nerve Outcomes. ( 29227438 )
2018
44
Ophthalmic Complications Following Acoustic Neuroma Resection. ( 29253289 )
2018
45
The Top 50 Most-Cited Articles on Acoustic Neuroma. ( 29288105 )
2018
46
The impact of acoustic neuroma on long-term quality-of-life outcomes in the United Kingdom. ( 29330600 )
2018
47
Patient Decision Making in Vestibular Schwannoma: A Survey of the Acoustic Neuroma Association. ( 29436268 )
2018
48
Risk of posterior semicircular canal trauma when using a retrosigmoid approach for acoustic neuroma surgery and role of endoscopy: An imaging study. ( 29493720 )
2018
49
Long-term outcome after Gamma Knife radiosurgery for acoustic neuroma of all Koos grades: a single-center study. ( 29498575 )
2018
50
The medium and long-term effect of electrophysiologic monitoring on the facial nerve function in minimally invasive surgery treating acoustic neuroma. ( 29563978 )
2018
Sources

Variations for Neuroma

About this section
Sources

Expression for Neuroma

About this section
Search GEO for disease gene expression data for Neuroma.
Sources

Pathways for Neuroma

About this section

Pathways related to Neuroma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Signaling by GPCR 67
Show member pathways
 13.76 CALCA FGF2 GDNF GFAP NF1 NF2
2
Developmental Biology 67
Show member pathways
 12.97 ANK3 FGF2 GDNF NF1 NRP1 RET
3
Immune response IFN alpha/beta signaling pathway 23
Show member pathways
 11.88 FGF2 NGF NRP1 TGFB1
4
Neuroscience 4
11.86 CALCA ENO2 GFAP NF1 NF2 NGF
5
L1CAM interactions 67
Show member pathways
 11.71 ANK3 NRP1 SCN10A
6
Spinal Cord Injury 1
11.66 GDNF GFAP TGFB1
7
Neural Stem Cell Differentiation Pathways and Lineage-specific Markers 66
11.25 FGF2 GDNF GFAP NGF S100B
8
Lung fibrosis 1
11.23 CALCA FGF2 TGFB1
Sources

GO Terms for Neuroma

About this section

Cellular components related to Neuroma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.97 CALCA FGF2 GDNF NGF NRP1 S100B
2 extracellular space GO:0005615 9.81 ACTA2 CALCA ENO2 FGF2 NGF NRP1
3 cell body GO:0044297 9.5 ACTA2 GFAP NF2
4 neuronal cell body GO:0043025 9.35 ENO2 NRP1 RET S100B TGFB1
5 neurofilament GO:0005883 9.26 GFAP NRP1
6 axon GO:0030424 9.17 ANK3 NF1 NGF NRP1 RET SCN10A

Biological processes related to Neuroma according to GeneCards Suite gene sharing:

(show all 35)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of apoptotic process GO:0043065 9.96 NF1 NGF S100B TGFB1
2 regulation of signaling receptor activity GO:0010469 9.96 CALCA FGF2 GDNF NGF TGFB1
3 positive regulation of gene expression GO:0010628 9.91 ACTA2 ANK3 NGF RET TGFB1
4 axon guidance GO:0007411 9.87 GDNF NRP1 RET SEMA3F
5 wound healing GO:0042060 9.82 FGF2 NF1 TGFB1
6 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.79 FGF2 NRP1 TGFB1
7 response to wounding GO:0009611 9.78 GFAP NRP1 TGFB1
8 positive regulation of endothelial cell proliferation GO:0001938 9.76 FGF2 NF1 NRP1
9 positive regulation of branching involved in ureteric bud morphogenesis GO:0090190 9.66 GDNF TGFB1
10 hyaluronan catabolic process GO:0030214 9.65 FGF2 TGFB1
11 negative regulation of cell-cell adhesion GO:0022408 9.65 NF2 TGFB1
12 neural crest cell migration GO:0001755 9.65 GDNF RET SEMA3F
13 lens fiber cell differentiation GO:0070306 9.64 NF2 TGFB1
14 commissural neuron axon guidance GO:0071679 9.63 GDNF NRP1
15 enteric nervous system development GO:0048484 9.63 GDNF RET
16 semaphorin-plexin signaling pathway involved in axon guidance GO:1902287 9.62 NRP1 SEMA3F
17 positive regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001241 9.62 NF1 RET
18 facial nerve structural organization GO:0021612 9.6 NRP1 SEMA3F
19 sympathetic ganglion development GO:0061549 9.59 NRP1 SEMA3F
20 axon extension involved in axon guidance GO:0048846 9.58 NRP1 SEMA3F
21 branchiomotor neuron axon guidance GO:0021785 9.55 NRP1 SEMA3F
22 MAPK cascade GO:0000165 9.55 FGF2 GDNF NF1 RET TGFB1
23 negative regulation of neuroblast proliferation GO:0007406 9.54 NF1 TGFB1
24 neural crest cell migration involved in autonomic nervous system development GO:1901166 9.52 NRP1 SEMA3F
25 ureteric bud development GO:0001657 9.5 GDNF RET TGFB1
26 trigeminal nerve structural organization GO:0021637 9.49 NRP1 SEMA3F
27 semaphorin-plexin signaling pathway involved in neuron projection guidance GO:1902285 9.46 NRP1 SEMA3F
28 sympathetic neuron projection extension GO:0097490 9.43 NRP1 SEMA3F
29 peripheral nervous system development GO:0007422 9.43 GDNF NF1 NGF
30 sympathetic neuron projection guidance GO:0097491 9.4 NRP1 SEMA3F
31 ventral trunk neural crest cell migration GO:0036486 9.37 NRP1 SEMA3F
32 response to pain GO:0048265 9.36 RET
33 sympathetic nervous system development GO:0048485 9.13 GDNF NF1 NRP1
34 nerve development GO:0021675 8.8 NGF NRP1 SEMA3F
35 positive regulation of transcription, DNA-templated GO:0045893 10.04 ACTA2 BICRA FGF2 RET TGFB1

Molecular functions related to Neuroma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 8.92 FGF2 GDNF NGF TGFB1
Sources

Sources for Neuroma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....